PRODUCTS R&D
Products

PRRSQTM The 1st PRRS SUBUNIT VACCINE

 

•  PRRSQTM PRRS subunit vaccine-Product features

   
    The PRRSQTM subunit vaccine is the 1st commercial PRRS subunit vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) in the world. Through its unique antigen delivery platform, PRRSQTM PRRS subunit vaccine could induce both significant humoral and cell-mediated immune responses against PRRS virus, and promote CMI response rapidly and persistently. This PRRS subunit vaccine has demonstrated excellent induction of swine immune responses. It also has a safety profile that is superior to the current PRRS vaccines in the world.

•  The features of the PRRSQTM subunit vaccine are：

1.    Uses the Pseudomonas exotoxin A as an antigen delivery platform
2.    Induces both humoral and cell-mediated immune responses
3.    Intercepts the epitope of neutralization antibody titration in PRRSV virus, and thus effectively reduce ADE (Antibody Dependent Enhancement).
4.    Includes both North American strain and the European strain of the PRRS antigen
5.    Significantly reduces the morbidity and mortality caused by PRRSV
6.    Does not induce allergic or immunotoxic reactions in lungs or skin.

•  Field trials show that  PRRSQTM subunit vaccine is safe and effective

1.    Significant reduction of abortion rate, stillbirth and reductive failure caused by PRRSV
2.    Significant improvements in livability at birth, the average litter size, litter weight of newborn piglets
3.    Significant reduction in levels and duration of viremia
4.    Significant reduction of PRRS-induced lung lesions; gross & microscopic
5.    Improve the growth performance of piglets
6.    Provides good protection to sows and piglets 
 

•  Packaging：50 dose/vial



 

CIRCOQTM PCV2 SUBUNIT VACCINE

 

• CIRCOQTM PCV2 subunit vaccine-Product features

   

    The CIRCOQTM subunit vaccine is a target subunit vaccine for Porcine Circovirus type 2 (PCV2) developed by Reber Genetics. The core technology of Reber Genetics is to combine two of the latest genetic engineering techniques, “reverse genetic engineering” and “fusion protein platform” to develop a series of targeted subunit animal vaccines.  CIRCOQTM can not only induce Neutralize antibodies and induce cellular immunity to improve overall protection of the herd.

 

 

•  Field trials show that CIRCOQ PCV2 subunit vaccine is safe and effective
 

1.    Provides the overall protection and improve total antibody uniformity of the herd.
2.    Less maternal derived antibodies interference from sow.
3.    Significant reduction in levels and duration of viremia
4.    Significant inducing cellular immunity against PCV2.
5.    Improve the survival rate.
6.    Improve the growth performance and reach the market weight eariler.
 

•  Packaging：100 dose/vial